Ian Smith

Summary

Affiliation: Royal Marsden Hospital
Country: UK

Publications

  1. ncbi request reprint Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy
    Ian E Smith
    Breast Unit, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    J Steroid Biochem Mol Biol 86:289-93. 2003
  2. pmc A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer
    R L Jones
    Breast Unit, Royal Marsden NHS Trust, London, UK
    Br J Cancer 100:305-10. 2009
  3. pmc Survival from breast cancer in England and Wales up to 2001
    A Leary
    Breast Unit, Royal Marsden Hospital, NHS Foundation Trust, Fulham Road, London SW3 6JJ, London, UK
    Br J Cancer 99:S56-8. 2008
  4. pmc Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma
    R L Jones
    Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK, and Molecular and Cellular Pathology, School of Medicine, University of Queensland, Mayne Medical School, Herston, Australia
    Br J Cancer 94:358-62. 2006
  5. ncbi request reprint Follow-up tests to detect recurrent disease: patient's reassurance or medical need?
    Ian E Smith
    The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK Electronic address
    Breast 22:S156-60. 2013
  6. pmc Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer
    Isabel F Pinhel
    Department of Academic Biochemistry, Institute of Cancer Research, London, UK
    Breast Cancer Res 12:R76. 2010
  7. pmc The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis
    Susan J Cleator
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, SW3 6JB, London, UK
    Breast Cancer Res 8:R32. 2006
  8. ncbi request reprint 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
    Ian Smith
    Royal Marsden Hospital, London, UK
    Lancet 369:29-36. 2007
  9. ncbi request reprint Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
    Ian E Smith
    Breast Unit, Royal Marsden Hospital, London SW3 6JJ, UK
    J Clin Oncol 23:5108-16. 2005
  10. ncbi request reprint A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer
    Ian E Smith
    Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom
    J Clin Oncol 25:3816-22. 2007

Detail Information

Publications84

  1. ncbi request reprint Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy
    Ian E Smith
    Breast Unit, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    J Steroid Biochem Mol Biol 86:289-93. 2003
    ..These results indicate that letrozole is more active than tamoxifen both as neoadjuvant therapy and as first-line treatment in advanced disease. They support the importance of current adjuvant trials comparing the two treatments...
  2. pmc A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer
    R L Jones
    Breast Unit, Royal Marsden NHS Trust, London, UK
    Br J Cancer 100:305-10. 2009
    ..Accelerated AC and EC with pegfilgrastim are safe and feasible regimens in the treatment of early breast cancer with less neutropenia than conventional 3 weekly schedules...
  3. pmc Survival from breast cancer in England and Wales up to 2001
    A Leary
    Breast Unit, Royal Marsden Hospital, NHS Foundation Trust, Fulham Road, London SW3 6JJ, London, UK
    Br J Cancer 99:S56-8. 2008
  4. pmc Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma
    R L Jones
    Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK, and Molecular and Cellular Pathology, School of Medicine, University of Queensland, Mayne Medical School, Herston, Australia
    Br J Cancer 94:358-62. 2006
    ....
  5. ncbi request reprint Follow-up tests to detect recurrent disease: patient's reassurance or medical need?
    Ian E Smith
    The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK Electronic address
    Breast 22:S156-60. 2013
    ..Monitoring for long-term sequelae of treatment is becoming as important as the detection of recurrence in an era where long-term survival is increasingly common. ..
  6. pmc Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer
    Isabel F Pinhel
    Department of Academic Biochemistry, Institute of Cancer Research, London, UK
    Breast Cancer Res 12:R76. 2010
    ..The aim of this study was to characterize the differences in immunoreactivity of common biomarkers that may occur (a) due to tissue handling at surgery and (b) between core-cuts and resected tumours...
  7. pmc The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis
    Susan J Cleator
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, SW3 6JB, London, UK
    Breast Cancer Res 8:R32. 2006
    ..The aim of this study was to examine the effect of the cellular composition of biopsies on the error rates of multigene predictors of response of breast tumours to neoadjuvant adriamycin and cyclophosphamide (AC) chemotherapy...
  8. ncbi request reprint 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
    Ian Smith
    Royal Marsden Hospital, London, UK
    Lancet 369:29-36. 2007
    ..We investigated the drug's effect on overall survival after a median follow-up of 2 years in the Herceptin Adjuvant (HERA) study...
  9. ncbi request reprint Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
    Ian E Smith
    Breast Unit, Royal Marsden Hospital, London SW3 6JJ, UK
    J Clin Oncol 23:5108-16. 2005
    ....
  10. ncbi request reprint A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer
    Ian E Smith
    Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom
    J Clin Oncol 25:3816-22. 2007
    ..We have therefore investigated whether neoadjuvant gefitinib, an EGFR inhibitor, might overcome biologic and clinical resistance to neoadjuvant anastrozole in a phase II placebo-controlled trial...
  11. ncbi request reprint Goals of treatment for patients with metastatic breast cancer
    Ian Smith
    The Royal Marsden Hospital, London, UK
    Semin Oncol 33:S2-5. 2006
    ....
  12. ncbi request reprint Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines
    Ian E Smith
    Royal Marsden Hospital Institute of Cancer Research, London, United Kingdom
    J Clin Oncol 24:2444-7. 2006
    ..Their use is sometimes extended to younger women after chemotherapy-induced amenorrhoea; we have audited this in one institution's breast unit, and we propose guidelines for use in such circumstances...
  13. ncbi request reprint Overview of gemcitabine activity in advanced breast cancer
    Ian E Smith
    Breast Unit, Royal Marsden Hospital, London, UK
    Semin Oncol 33:S19-23. 2006
    ..These results have prompted ongoing trials of gemcitabine in early breast cancer as neoadjuvant and adjuvant therapy...
  14. doi request reprint First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients
    I E Smith
    Breast Unit, Royal Marsden Hospital, London, and the Institute of Cancer Research, London, UK
    Ann Oncol 22:595-602. 2011
    ..This large, open-label study further assesses first-line bevacizumab with taxane-based chemotherapy in routine oncology practice...
  15. pmc New approaches to the management of early breast cancer
    I E Smith
    Department of Medicine, Royal Marsden Hospital, London, UK
    Cancer Imaging 10:S51-3. 2010
    ..It is clear that breast cancer is no longer one disease but a heterogeneous group of subtypes, each with their own biology and pattern of clinical behaviour...
  16. doi request reprint Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial
    Ian Smith
    Breast Unit, Royal Marsden Hospital, London, SW3 6JJ, UK
    Breast Cancer Res Treat 130:133-43. 2011
    ..In the absence of progression, continuation of single-agent bevacizumab appears to be a reasonable approach, with minimal toxicity and the possibility of long-term disease control...
  17. ncbi request reprint The evolution of adjuvant endocrine therapy: developments since St Gallen 2005
    Ian E Smith
    Breast Unit, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Breast 16:S4-9. 2007
    ....
  18. pmc Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial
    Paul Ellis
    Guy s and St Thomas NHS Trust, London, UK
    Lancet 373:1681-92. 2009
    ..The UK TACT study (CRUK01/001) investigated whether sequential docetaxel after anthracycline chemotherapy would improve patient outcome compared with standard chemotherapy of similar duration...
  19. pmc Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]
    Trevor Powles
    Parkside Oncology, London, UK
    Breast Cancer Res 8:R13. 2006
    ....
  20. doi request reprint Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, UK
    J Natl Cancer Inst Monogr 2011:120-3. 2011
    ..It provides a unique opportunity for detailed study of the determinants of response and resistance to estrogen deprivation as well as testing the role of presurgical therapy for improved biomarker-based estimates of prognosis...
  21. ncbi request reprint Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists
    Mitch Dowsett
    Academic Department of Biochemistry and the Breast Unit, Royal Marsden Hospital, London SW3 6JJ, UK
    J Clin Oncol 23:2477-92. 2005
    ..To investigate the relationships between biomarker changes in breast cancer during neoadjuvant (preoperative) endocrine therapy...
  22. ncbi request reprint Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance
    Stephen R D Johnston
    Department of Medicine Breast Unit, The Royal Marsden NHS Trust, 233 Fulham Road, London SW3 6JJ, UK
    J Steroid Biochem Mol Biol 95:173-81. 2005
    ..This article reviews the pre-clinical rationale for this strategy and the clinical trials in this area...
  23. ncbi request reprint Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy
    Marina Parton
    Breast Unit, Royal Marsden NHS Trust and Institute of Cancer Research, London SW3 6JJ, United Kingdom
    Clin Cancer Res 8:2100-8. 2002
    ..Therefore, the relationship between key components of this machinery was examined in primary human breast carcinomas before and 24 h after the initiation of chemotherapy...
  24. ncbi request reprint Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London
    Clin Cancer Res 11:951s-8s. 2005
    ....
  25. doi request reprint Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial
    Hatem A Azim
    Jose Baselga, Memorial Sloan Kettering Cancer Center, NY James G Greger Jr, GlaxoSmithKline, Collegeville, PA Hatem A Azim Jr, Martine Piccart, Evandro de Azambuja, BrEAST Data Centre, Institut Jules Bordet, Université Libre de Bruxelles Phuong Dinh, Breast International Group, Brussels Peter Vuylsteke, Sint Elisabeth Hospital, Namur, Belgium Dominique Agbor tarh, Ian Bradbury, Frontier Science, Kincraig, Kingussie, Scotland Ian Smith, Royal Marsden Hospital, and Institute of Cancer Research, London, United Kingdom Serena Di Cosimo, IRCCS Fondazione Instituto Nazionale dei Tumori, Milan, Italy Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain Christian Jackisch, Kilinikum Offenbach, Offenbach Bahriye Aktas, Kliniken Essen Mitte, Evang,
    J Clin Oncol 31:4504-11. 2013
    ....
  26. doi request reprint Time trends in the outcome of elderly patients with breast cancer
    Sarah Hughes
    The Royal Marsden Hospital, Surrey, United Kingdom
    Breast J 14:158-63. 2008
    ..More clinical trials for older women are needed, if the benefits of recent advances in the management of this disease are to be extended to the over 70s. These data should, however, act as a benchmark for future audits...
  27. ncbi request reprint Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response
    Robin L Jones
    Breast Unit, Royal Marsden Hospital, London, UK
    Lancet Oncol 7:869-74. 2006
    ..In addition, the anatomical accessibility of the breast provides the potential for serial biopsies to investigate molecular changes during treatment...
  28. pmc Medical treatment of early breast cancer. IV: neoadjuvant treatment
    Ian Smith
    Royal Marsden Hospital, London
    BMJ 332:223-4. 2006
  29. ncbi request reprint Factors determining outcome after third line chemotherapy for metastatic breast cancer
    Udai Banerji
    The Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, London, UK
    Breast 16:359-66. 2007
    ..Patients who do not respond to the first two lines of chemotherapy should be considered for clinical trials or supportive care...
  30. ncbi request reprint Adjuvant endocrine therapy for early breast cancer
    Claudia Andreetta
    Royal Marsden Hospital, Fulham Road, London, UK
    Cancer Lett 251:17-27. 2007
    ..Issues including the timing of administration (up-front or sequential), the duration of the therapy and the role of biomarkers such as PgR and HER2 in optimal selection remain unresolved...
  31. ncbi request reprint Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer
    Mitch Dowsett
    Academic Department of Biochemistry and Breast Unit, Royal Marsden Hospital, London SW3 6JJ, United Kingdom
    Clin Cancer Res 12:1024s-1030s. 2006
    ..We argue that these changes in proliferation and concurrent changes in apoptosis may be expected to be more predictive of adjuvant benefit from endocrine therapy than clinical response...
  32. doi request reprint Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer
    Robin L Jones
    Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Breast Cancer Res Treat 119:315-23. 2010
    ..Ki67 is not an independent predictor of clinical CR or pCR. Aspects of ER status beyond its inverse relationship with proliferation may contribute to its predictive value for pCR...
  33. ncbi request reprint Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
    Mitch Dowsett
    Academic Department of Biochemistry, 4th Floor, Wallace Wing, The Royal Marsden Hospital, Fulham Road, London SW3 6 JJ, UK
    J Natl Cancer Inst 99:167-70. 2007
    ....
  34. pmc Medical treatment of early breast cancer. I: adjuvant treatment
    Ian Smith
    Royal Marsden Hospital, London
    BMJ 332:34-7. 2006
  35. ncbi request reprint Routine prophylactic granulocyte colony stimulating factor (GCSF) is not necessary with accelerated (dose dense) paclitaxel for early breast cancer
    Monica Arnedos
    Breast Unit, The Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK
    Breast Cancer Res Treat 112:1-4. 2008
    ..We have reviewed a series of patients with early breast cancer treated with accelerated 2-weekly paclitaxel without routine GCSF to assess its need...
  36. doi request reprint The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer
    Susana Banerjee
    Breakthrough Breast Cancer Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 14:2656-63. 2008
    ..We investigated the effects of anastrozole and tamoxifen over time on serum VEGF and sVEGFR-1...
  37. ncbi request reprint Is there still a role for neoadjuvant therapy in breast cancer?
    Catherine Shannon
    Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK
    Crit Rev Oncol Hematol 45:77-90. 2003
    ..The potential for biological surrogate markers of response to predict for long-term outcome may allow individualisation of systemic treatment and the rapid assessment of new drugs in early breast cancer...
  38. ncbi request reprint Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer
    Trevor Powles
    Royal Marsden National Health Service Trust, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    J Clin Oncol 20:3219-24. 2002
    ..Given to patients with primary breast cancer, clodronate might reduce the subsequent incidence of bone metastases...
  39. doi request reprint Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Anastasia Constantinidou
    Breast Unit, Royal Marsden Hospital, London UK and Institute of Cancer Research, London, UK
    Breast 20:S158-61. 2011
    ..Meanwhile there is already enough circumstantial evidence to justify anti-HER2 therapy alone in selected patients for whom chemotherapy is contraindicated...
  40. ncbi request reprint Mechanisms of resistance to aromatase inhibitors
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, UK
    J Steroid Biochem Mol Biol 95:167-72. 2005
    ..Collection of resistant biopsy tissues from patients is important to determine if this mechanism is clinically relevant...
  41. pmc Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women
    Anita K Dunbier
    Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Rd, London, SW3 6JJ, United Kingdom
    J Clin Oncol 28:1161-7. 2010
    ..The AvERG is a new experimental tool for the study of putative estrogenic stimuli of breast cancer...
  42. ncbi request reprint Aromatase inhibitors in early breast cancer therapy
    Ian E Smith
    Royal Marsden Hospital, Institute of Cancer Research, London, United Kingdom
    Semin Oncol 31:9-14. 2004
    ..While all three aromatase inhibitors as adjuvant therapy were well tolerated, long-term effects on bone health and lipids are being monitored. Ongoing trials will better define the optimum use of aromatase inhibitors as adjuvant therapy...
  43. ncbi request reprint Aromatase inhibitors--extending the benefits of adjuvant therapy beyond tamoxifen
    Ian E Smith
    Royal Marsden Hospital, Surrey, England, UK
    Breast 13:S3-9. 2004
    ..This review will examine the published data, discuss ongoing trials, and address the question of how to best integrate the aromatase inhibitors into adjuvant treatment...
  44. ncbi request reprint Hormonal therapy: introduction
    Ian E Smith
    The Royal Marsden Hospital, Sutton, Surrey, UK
    Breast 12:S1. 2003
  45. ncbi request reprint Progression of endocrine therapies for breast cancer: where are we headed?
    Monica Arnedos
    The Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK
    Expert Rev Anticancer Ther 7:1651-64. 2007
    ..A key question for all forms of endocrine therapy remains optimal duration. Evidence is emerging to suggest that, for some women, treatment should be continued for many years and perhaps lifelong...
  46. pmc Medical treatment of early breast cancer. III: chemotherapy
    Ian Smith
    Royal Marsden Hospital, London
    BMJ 332:161-2. 2006
  47. doi request reprint Sternal/para-sternal resection for parasternal local recurrence in breast cancer
    Jill Noble
    Breast Unit, The Royal Marsden NHS Foundation Trust, Fulham Road, London, UK
    Breast 19:350-4. 2010
    ..This can result in substantial morbidity and mortality. Chest wall resection is well-documented for palliation and local control in chest wall relapse; an extension of this surgery is parasternal or sternal resection...
  48. ncbi request reprint New drugs for breast cancer
    Ian E Smith
    Breast Unit, Royal Marsden Hospital, London SW3 6JJ, UK
    Lancet 360:790-2. 2002
  49. doi request reprint The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer
    Robin L Jones
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    Breast Cancer Res Treat 116:53-68. 2009
    ..To compare the prognostic significance of proliferation, as assessed by Ki67 expression, in breast cancer before and after neoadjuvant chemotherapy...
  50. ncbi request reprint Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals
    Alistair E Ring
    Breast Unit, Royal Marsden Hospital, Guy s, King s and St Thomas Cancer Centre, London, United Kingdom
    J Clin Oncol 23:4192-7. 2005
    ..In this retrospective case series, we describe the experiences of five hospitals in London, United Kingdom, and how they manage this condition...
  51. doi request reprint Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women
    Marina Parton
    Breast Unit, The Royal Marsden Hospital, Institute of Cancer Research, London, United Kingdom
    J Clin Oncol 26:745-52. 2008
  52. ncbi request reprint Predictors of response to aromatase inhibitors
    Helen Anderson
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, UK
    J Steroid Biochem Mol Biol 106:49-54. 2007
    ..Analysis of multiple gene expression changes over a short treatment period may also have potential clinical utility for prediction of response...
  53. pmc Medical treatment of early breast cancer. II: endocrine therapy
    Ian Smith
    Royal Marsden Hospital, London
    BMJ 332:101-3. 2006
  54. pmc Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial
    Sally Moore
    Centre for Cancer and Palliative Care Studies, Institute of Cancer Research, Royal Marsden Hospital, London SW3 6JJ
    BMJ 325:1145. 2002
    ..To assess the effectiveness of nurse led follow up in the management of patients with lung cancer...
  55. ncbi request reprint Breast cancer
    Alistair Ring
    Department of Medicine, Breast Unit, Royal Marsden Hospital, London, UK
    Cancer Chemother Biol Response Modif 22:545-61. 2005
  56. ncbi request reprint Aromatase inhibitors in breast cancer
    Ian E Smith
    Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom
    N Engl J Med 348:2431-42. 2003
  57. ncbi request reprint Efficacy and safety of trastuzumab
    Robin L Jones
    Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK
    Expert Opin Drug Saf 3:317-27. 2004
    ..Cross-talk' between the oestrogen receptor and HER2 pathway has stimulated interest in using trastuzumab in combination with endocrine therapy. Current clinical trials are investigating the role of this agent in the adjuvant setting...
  58. ncbi request reprint Enhancing endocrine response with novel targeted therapies: why have the clinical trials to date failed to deliver on the preclinical promise?
    Stephen R D Johnston
    Department of Medicine, Royal Marsden Hospital, Fulham Road, Chelsea, London, UK
    Cancer 112:710-7. 2008
    ....
  59. ncbi request reprint Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer
    Edurne Arriola
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    Breast Cancer Res Treat 106:181-9. 2007
    ....
  60. ncbi request reprint Phase II studies of pemetrexed in metastatic breast and gynecologic cancers
    Ian Smith
    Medical Oncologist Royal Marsden Hospital, London, United Kingdom
    Oncology (Williston Park) 18:63-5. 2004
    ..Ongoing and future studies will establish optimal dosing regimens of pemetrexed and potential benefits of vitamin supplementation in the settings of metastatic breast cancer and gynecologic malignancies...
  61. doi request reprint Intratumoral estrogen disposition in breast cancer
    Ben P Haynes
    Academic Biochemistry and Medicine, Royal Marsden Hospital, London, United Kingdom
    Clin Cancer Res 16:1790-801. 2010
    ..The contribution of local E(2) synthesis versus uptake of E(2) from the circulation is controversial. Our aim was to identify possible determinants of intratumoral E(2) levels in breast cancer patients...
  62. ncbi request reprint Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer
    Stephen R D Johnston
    Departments of Medicine and Academic Biochemistry, Royal Marsden Hospital and Institute of Cancer Research, London SW3 6JJ, United Kingdom
    Clin Cancer Res 9:524S-32S. 2003
    ....
  63. ncbi request reprint Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab
    Thomas Yau
    Breast Unit, Royal Marsden Hospital, Surrey SM2 5PT, UK
    Acta Oncol 45:196-201. 2006
    ..This study shows brain metastases are common phenomenon in HER2 positive advanced breast cancer patients receiving trastuzumab and also may implicate the brain as a sanctuary site for early relapse in this patient cohort...
  64. ncbi request reprint Proliferation marker Ki-67 in early breast cancer
    Ander Urruticoechea
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, United Kingdom
    J Clin Oncol 23:7212-20. 2005
    ..However, its application as a pharmacodynamic intermediate marker of the effectiveness of medical therapy holds great promise for rapid evaluation of new drugs...
  65. ncbi request reprint Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients
    David S P Tan
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK
    Breast Cancer Res Treat 111:27-44. 2008
    ....
  66. ncbi request reprint A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer
    Hugo E R Ford
    Department of Medicine, Breast Unit, Royal Marsden NHS Trust, 233 Fulham Road, SW3 6JJ, London, United Kingdom
    Cancer Chemother Pharmacol 58:809-15. 2006
    ..We evaluated the toxicity and the activity of weekly docetaxel in anthracycline-pretreated patients...
  67. ncbi request reprint Circulating tumour cells in breast cancer
    Alistair Ring
    Academic Department of Biochemistry and the Breast Unit, Royal Marsden Hospital, London, UK
    Lancet Oncol 5:79-88. 2004
    ..We also review the clinical studies in breast cancer and discuss the potential relevance of this research to the future management of the disorder...
  68. ncbi request reprint Chronic treatment with modafinil may not be beneficial in patients with chronic fatigue syndrome
    Delia C Randall
    Psychopharmacology Research Unit, Centre for Neuroscience Research, King s College London, London, UK
    J Psychopharmacol 19:647-60. 2005
    ..It is discussed whether the limited and mixed cognitive effects that we observed could have occurred by chance, or whether a subgroup of CFS patients with daytime sleepiness would have shown greater benefits...
  69. doi request reprint Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects
    Sanjay Popat
    Royal Marsden Hospital and Imperial College, London, UK
    Nat Clin Pract Oncol 5:324-35. 2008
    ....
  70. ncbi request reprint Cell filtration-laser scanning cytometry for the characterisation of circulating breast cancer cells
    Lila Zabaglo
    Academic Department of Biochemistry, Royal Marsden Hospital, London, United Kingdom
    Cytometry A 55:102-8. 2003
    ..Additionally, biomarker analysis may allow a more rational approach to therapeutics. We have developed a new method for the detection and characterisation of these cells...
  71. ncbi request reprint Re: Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis
    Sanjay Popat
    J Natl Cancer Inst 97:858; author reply 858-9. 2005
  72. ncbi request reprint Trastuzumab for early breast cancer
    Ian E Smith
    Lancet 367:107. 2006
  73. ncbi request reprint Breast radiotherapy after lumpectomy--no longer always necessary
    Ian E Smith
    N Engl J Med 351:1021-3. 2004
  74. ncbi request reprint Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial
    Trevor J Powles
    Parkside Oncology Clinic, 49 Parkside, Wimbledon, London SW19 5NB, UK
    J Natl Cancer Inst 99:283-90. 2007
    ..We report the blinded 20-year follow-up (median follow-up = 13 years) of the Royal Marsden trial to identify any long-term prevention of breast cancer associated with tamoxifen treatment...
  75. ncbi request reprint Challenges in the endocrine management of breast cancer
    Henning T Mouridsen
    Department of Oncology, Rigshospitalet, Copenhagen, Denmark
    Breast 12:S2-19. 2003
    ..These assessments also clearly indicated the eagerness of patients to participate actively in treatment decisions..
  76. doi request reprint Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease
    Julie R Gralow
    Seattle Cancer Care Alliance, Department of Medicine, 825 Eastlake Ave, EMS G3 200, Seattle, WA 98109 1023, USA
    J Clin Oncol 26:814-9. 2008
    ..To review the state of the science with respect to preoperative systemic therapy and pathologic assessment in operable breast cancer...
  77. doi request reprint Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial
    Diana Crivellari
    IBCSG Coordinating Center, Effingerstrasse 40, CH 3008 Bern, Switzerland
    J Clin Oncol 26:1972-9. 2008
    ..To explore potential differences in efficacy, treatment completion, and adverse events (AEs) in elderly women receiving adjuvant tamoxifen or letrozole for five years in the Breast International Group (BIG) 1-98 trial...
  78. ncbi request reprint Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC)
    Ander Urruticoechea
    Institut Catala d Oncologia, Hospital Duran i Reynalds, Gran Via km 2 7 L Hospitalet de Llobregat, Barcelona, Spain
    Breast Cancer Res Treat 110:411-6. 2008
    ..We report an audit of our experience with the luteinising hormone-releasing hormone agonist, goserelin, to achieve transient ovarian suppression during chemotherapy as a means of preserving ovarian function...
  79. ncbi request reprint Domiciliary-assisted ventilation in patients with myotonic dystrophy
    Anne Marie Nugent
    Respiratory Support and Sleep Center, Papworth Hospital, Papworth Everard, Cambridge, United Kingdom
    Chest 121:459-64. 2002
    ..The purpose of this study was to review the use of domiciliary-assisted ventilation in these patients and to assess their response to treatment...
  80. ncbi request reprint Obstructive sleep apnoea in the elderly: recognition and management considerations
    Timothy G Quinnell
    Respiratory Support and Sleep Centre, Papworth Hospital, Papworth Everard, Cambridge CB3 8RE, UK
    Drugs Aging 21:307-22. 2004
    ..Specific serotonergic agonists hold the greatest potential for a useful drug treatment for this widespread and debilitating condition...